MS
MDGL icon

Maven Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

Maven Securities’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,298
Closed -$482K – 1090
2023
Q3 		$482K Buy
+3,298
New +$621K 0.01% 822
2021
Q3 		– Sell
-50,000
Closed -$4.91M – 1180
2021
Q2 		$4.91M Buy
+50,000
New +$5.92M 0.2% 89

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Maven Securities's MDGL Position: Q4 2023 in Review

Maven Securities sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 3,298 shares — an estimated $482K sold.

Maven Securities first reported a position in MDGL in Q2 2021 and held it in 2 quarters. The position peaked at $4.91M in Q2 2021. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

  • Maven Securities reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Maven Securities sold 3,298 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $482K.
  • Maven Securities first reported a position in Madrigal Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Maven Securities's Madrigal Pharmaceuticals position peaked at $4.91M in Q2 2021.
  • 226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on Maven Securities's 13F filing for Q4 2023, filed 12 Feb 2024.